Momo Wu

Director / Emerson Collective

Momo is the investment director at Emerson Collective, an impact investing family office in Bay Area. She is involved with more than 50 companies financing of early-stage oncology biotech companies including therapeutics and diagnostics and has been active board member and board observer to her portfolio companies. Some of her notable early-stage investments include NKarta (NKTA), EQRX (EQRX),Thrive (Acquired for 2.1B) and Resilience.

Previously she was at Taiwan Global Biofund, which invested in early stage biotech companies in both Asia and US. She also spent a couple years at McKinsey & Co. Silicon Valley Office working on Pharma and Medtech global strategy and pipeline prioritizations. Momo got her PhD in Pharmaceutical Science and Pharmacogenomics from UCSF specialized in pharmacokinetic and pharmacodynamic research and a B.S from National Taiwan University.

Momo是Emerson Collective 家族基金的專業基金經理人，前麥肯錫顧問（矽谷分公司），在生技產業已經有超過十年的經歷，他投資早期生技公司，包含新藥以及檢驗試劑。在2020年，她已超過200% 年投報率的成功出場三間公司(兩間被上市公司收購，一間在Nasdaq公開發行)，其中Thrive 是以＄21億美金被收購。Ｍomo也在投資後擔任董事，積極協助新創公司。她擁有台大生化科技學系學士學位以及ＵＣＳＦ藥學博士學位。